INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Feb 12, 2026

TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - January 20, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Instil Bio, Inc. ("Instil Bio, Inc.") (NASDAQ: TIL) concerning potential violations of the federal securities laws. Instil issued a press release on January 6, 2026, announcing that Axion Bio, Inc. ("Axion"), an Instil subsidiary, "has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc..

Newsfile Corp • Jan 20, 2026

Instil Bio shares slide on discontinuation of lead clinical programs

Instil Bio (NASDAQ:TIL) shares plummeted 46% to about $7 after the company announced its decision to discontinue development of its lead clinical assets AXN-2510 and AXN-27M and to terminate its partnership with ImmuneOnco. Analysts at Baird downgraded the stock to ‘Neutral' on the update.

Proactive Investors • Jan 6, 2026

Instil Bio Pulls Plug On Lead Drug Development

Instil Bio, Inc. (NASDAQ: TIL) stock is trading lower on Tuesday. Axion Bio Inc., a wholly-owned subsidiary of Instil, decided to discontinue clinical development of AXN-2510.

Benzinga • Jan 6, 2026

Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”). Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind down its clinical development activities.

GlobeNewsWire • Jan 6, 2026

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its third quarter 2025 financial results and provided a corporate update. Recent Highlights: In September, ImmuneOnco, Instil's collaborator, presented updated data from additional patients with relapsed/refractory squamous non-small cell lung cancer treated with ‘2510 as monotherapy in a poster presentation at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.

GlobeNewsWire • Nov 13, 2025

Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF bispecifics DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK) (“ImmuneOnco”) presented preliminary efficacy and safety data of ‘2510 (IMM2510/AXN-2510) as monotherapy in a Phase 1 study of patients in China with previously treated squamous non-small cell lung cancer (sq-NSCLC) at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain on September 9, 2025.

GlobeNewsWire • Sep 10, 2025

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025

GlobeNewsWire • Aug 13, 2025

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line NSCLC ImmuneOnco expects to present updated safety and efficacy data at a future medical conference DALLAS and SHANGHAI, July 31, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) noted that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK) (“ImmuneOnco”), today announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of IMM2510/AXN-2510 (‘2510) in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China by ImmuneOnco. As of July 1, 2025, 33 patients were dosed at 10 mg/kg, with 21 patients having at least one tumor assessment (efficacy evaluable).

GlobeNewsWire • Jul 31, 2025

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the clearance of an Investigational New Drug (IND) application for AXN-2510 (“'2510”) by the U.S. Food and Drug Administration. Instil expects to initiate a phase 1 trial of ‘2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025.

GlobeNewsWire • Jul 2, 2025